AR086972A1 - Procesos para preparar compuestos heterociclicos, que incluyen trans-7-oxo-6-(sulfooxi)-1,6-diazabiciclo[3,2,1]octano-2-carboxamida y sales de la misma - Google Patents
Procesos para preparar compuestos heterociclicos, que incluyen trans-7-oxo-6-(sulfooxi)-1,6-diazabiciclo[3,2,1]octano-2-carboxamida y sales de la mismaInfo
- Publication number
- AR086972A1 AR086972A1 ARP120102159A AR086972A1 AR 086972 A1 AR086972 A1 AR 086972A1 AR P120102159 A ARP120102159 A AR P120102159A AR 086972 A1 AR086972 A1 AR 086972A1
- Authority
- AR
- Argentina
- Prior art keywords
- carbon atoms
- optionally substituted
- alkyl
- aryl
- aralkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Reivindicación 1: Un proceso para preparar un compuesto de fórmula (1), o una sal, solvato, hidrato, enantiómero o diastereómero farmacéuticamente aceptable de los mismos; caracterizado porque comprende (a) tratar un compuesto de fórmula (2) con una fuente de nitrógeno o una amina para preparar un compuesto de fórmula (3); y (b) tratar el compuesto de fórmula (3) con un grupo protector y un grupo saliente; en donde R1, R2, R3, R4, R5, R6 y R7 son idénticos o diferentes y se seleccionan independientemente del grupo que consiste en hidrógeno, oxígeno, nitrógeno, carbonilo, carbamoilo, alquilo, alquenilo, alquinilo, alcoxi, cicloalquilo, arilo, aralquilo, trialquilsililo y heterociclo; cada uno de R1, R2, R3, R4, R5, R6 y R7 está opcionalmente sustituido por uno o más halógeno, oxígeno, hidroxi, ciano, nitro, amino, alquilamino, dialquilamino, arilamino, diarilamino, amido, alquilamido, carbamoilo, ureido, dimetilamino, carboxilo, alquilo, alilo, alquilo halogenado, trialquilsililo, alquenilo, alquinilo, cicloalquilo, cicloalquilalquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclo, heterocicloalquilo, aroilo, acilo, alcoxi, ariloxi, heteroariloxi, cicloalquiloxi, cicloalquilalquiloxi, arilalquiloxi, heteroarilalquiloxi, alquiltio, ariltio, alquilsulfinilo, alquilsulfonilo, arilsulfinilo, arilsulfonilo, heteroarilsulfinilo, heteroarilsulfonilo alcoxicarbonilo, ariloxicarbonilo, heteroariloxicarbonilo o una combinación de los mismos; o R1 y R2 juntos forman un heterociclo; opcionalmente sustituido por uno o más halógeno, hidroxi, ciano, nitro, amino, alquilamino, dialquilamino, arilamino, diarilamino, amido, alquilamido, carbamoilo, ureido, dimetilamino, carboxilo, alquilo, alquilo halogenado, alquenilo, alquinilo, cicloalquilo, cicloalquilalquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclo, heterocicloalquilo, aroilo, acilo, alcoxi, ariloxi, heteroariloxi, cicloalquiloxi, cicloalquilalquiloxi, arilalquiloxi, heteroarilalquiloxi, alquiltio, ariltio, alquilsulfinilo, alquilsulfonilo, arilsulfinilo, arilsulfonilo, heteroarilsulfinilo, heteroarilsulfonilo alcoxicarbonilo, ariloxicarbonilo, heteroariloxicarbonilo o una combinación de los mismos; o R3 es COH, COB’, COOB’, CONH2, CONHB’, CONHOH, CONHSO2B’, CH2COOH, CH2COOB’, CH2CONHOH, CH2CONHCN, CH2-tetrazol, CH2-tetrazol protegido, CH2SO3H, CH2SO2B’, CH2PO(OB’)2, CH2PO(OB’)(OH), CH2PO(B’)(OH) y CH2PO(OH)2; en donde B’ se selecciona del grupo que consiste en alquilo que contiene 1 a 6 átomos de carbono opcionalmente sustituido por un radical piridilo o carbamoilo, -CH2-alquenilo que contiene 3 a 9 átomos de carbono, arilo que contiene 6 a 10 átomos de carbono y aralquilo que contiene 7 a 11 átomos de carbono; en donde el núcleo de dicho arilo o aralquilo está opcionalmente sustituido por OH, NH2, NO2, alquilo que contiene 1 a 6 átomos de carbono, alcoxi que contiene 1 a 6 átomos de carbono o por uno o más átomos de halógeno; o R3 es OR’ u OP’; en donde R’ se selecciona del grupo que consiste en SO3, SO2, SO2NHCOH, SO2NHCO, SO2NHCOO, SO2NHCONH y SO2NHCONH2; y R’ está opcionalmente sustituido por hidrógeno o un grupo alquilo opcionalmente sustituido por un radical piridilo o carbamoilo, -CH2-alquenilo que contiene 3 a 9 átomos de carbono, arilo que contiene 6 a 10 átomos de carbono y aralquilo que contiene 7 a 11 átomos de carbono; en donde el núcleo de dicho arilo o aralquilo está opcionalmente sustituido por OH, NH2, NO2, alquilo que contiene 1 a 6 átomos de carbono, alcoxi que contiene 1 a 6 átomos de carbono o por uno o más átomos de halógeno; y P’ se selecciona del grupo que consiste en PO(OH)2, PO3, PO2, PO, PO(OH)(O-), PO2NHCOH, PO2NHCO, PO2NHCOO, PO2NHCONH y PO2NHCONH2; y P’ está opcionalmente sustituido por hidrógeno o un grupo alquilo opcionalmente sustituido por un radical piridilo o carbamoilo, -CH2-alquenilo que contiene 3 a 9 átomos de carbono, arilo que contiene 6 a 10 átomos de carbono y aralquilo que contiene 7 a 11 átomos de carbono; en donde el núcleo de dicho arilo o aralquilo está opcionalmente sustituido por OH, NH2, NO2, alquilo que contiene 1 a 6 átomos de carbono, alcoxi que contiene 1 a 6 átomos de carbono o por uno o más átomos de halógeno.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161498522P | 2011-06-17 | 2011-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR086972A1 true AR086972A1 (es) | 2014-02-05 |
Family
ID=46317443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120102159 AR086972A1 (es) | 2011-06-17 | 2012-06-18 | Procesos para preparar compuestos heterociclicos, que incluyen trans-7-oxo-6-(sulfooxi)-1,6-diazabiciclo[3,2,1]octano-2-carboxamida y sales de la misma |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US8829191B2 (es) |
| EP (1) | EP2721005B1 (es) |
| JP (2) | JP6023800B2 (es) |
| KR (1) | KR102143660B1 (es) |
| CN (2) | CN105294690B (es) |
| AR (1) | AR086972A1 (es) |
| AU (1) | AU2012270051B2 (es) |
| BR (1) | BR112013032415B1 (es) |
| CA (1) | CA2780403C (es) |
| ES (1) | ES2560404T3 (es) |
| HK (1) | HK1196615A1 (es) |
| IL (1) | IL229815A (es) |
| MX (1) | MX361020B (es) |
| MY (1) | MY165730A (es) |
| RU (2) | RU2769076C2 (es) |
| SG (1) | SG195289A1 (es) |
| TW (1) | TWI565706B (es) |
| WO (1) | WO2012172368A1 (es) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8772490B2 (en) | 2010-12-22 | 2014-07-08 | Meiji Seika Pharma Co., Ltd. | Optically active diazabicyclooctane derivatives and process for preparing the same |
| WO2012133486A1 (ja) * | 2011-03-31 | 2012-10-04 | 株式会社カネカ | 環状アミン化合物の製造法 |
| ES2560404T3 (es) * | 2011-06-17 | 2016-02-18 | Astrazeneca Ab | Procesos para preparar compuestos heterocíclicos, incluida trans-7-oxo-6-(sulfooxi)-1,6-diazabiciclo[3,2,1]octano-2-carboxamida y sales de la misma |
| US8796257B2 (en) | 2011-12-02 | 2014-08-05 | Naeja Pharmaceutical Inc. | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors |
| US9505761B2 (en) | 2011-12-02 | 2016-11-29 | Fedora Pharmaceuticals Inc. | Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors |
| JP2015514095A (ja) | 2012-03-30 | 2015-05-18 | キュービスト ファーマシューティカルズ， インコーポレイテッド | １，３，４−オキサジアゾールおよび１，３，４−チアジアゾールβ−ラクタマーゼ阻害剤 |
| CA2869051A1 (en) | 2012-03-30 | 2013-10-03 | Cubist Pharmaceuticals, Inc. | Isoxazole .beta.-lactamase inhibitors |
| US8969570B2 (en) | 2012-03-30 | 2015-03-03 | Cubist Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US8916709B2 (en) | 2012-03-30 | 2014-12-23 | Cubist Pharmaceuticals, Inc. | 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors |
| ES2758507T3 (es) | 2012-05-30 | 2020-05-05 | Meiji Seika Pharma Co Ltd | Nuevo inhibidor de B-lactamasa y método para producir el mismo |
| US20150315145A1 (en) * | 2012-11-01 | 2015-11-05 | Kaneka Corporation | Process for producing optically active bicyclic urea compound |
| UA111925C2 (uk) * | 2012-12-11 | 2016-06-24 | Федора Фармасьютікалз Інк. | БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ |
| CN105164132A (zh) * | 2013-03-08 | 2015-12-16 | 沃克哈特有限公司 | (2s,5r)-6-苄氧基-7-氧代-1,6-二氮杂-双环[3.2.1]辛烷-2-羧酸钠及其制备方法 |
| JP6253676B2 (ja) * | 2013-03-08 | 2017-12-27 | ウォックハート リミテッド | （２ｓ，５ｒ）−２−カルボキシアミド−７−オキソ−６−スルホオキシ−１，６−ジアザ−ビシクロ［３．２．１］オクタンのナトリウム塩のためのプロセス |
| US9120795B2 (en) | 2013-03-14 | 2015-09-01 | Cubist Pharmaceuticals, Inc. | Crystalline form of a β-lactamase inhibitor |
| DK3050883T3 (da) * | 2013-09-24 | 2020-05-25 | Meiji Seika Pharma Co Ltd | Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter |
| US9120796B2 (en) | 2013-10-02 | 2015-09-01 | Cubist Pharmaceuticals, Inc. | B-lactamase inhibitor picoline salt |
| AR097971A1 (es) * | 2013-10-08 | 2016-04-20 | Meiji Seika Pharma Co Ltd | Formas cristalinas de derivado de diazabiciclooctano y proceso de producción de ellas |
| CA2934492A1 (en) * | 2014-01-21 | 2015-07-30 | Wockhardt Limited | Nitrogen containing compounds and their use |
| EP3116875A1 (en) * | 2014-03-14 | 2017-01-18 | Wockhardt Limited | A process for preparation of sodium (2s, 5r)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylate |
| EP3227306B1 (en) | 2014-12-02 | 2020-07-15 | Merck Sharp & Dohme Corp. | Process for the preparation of tert-butyl 4-((2s,5r)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamido)piperidine-1-carboxylate and analogs thereof |
| US10294224B2 (en) | 2014-12-05 | 2019-05-21 | Meiji Seika Pharma Co., Ltd. | Lyophilized composition of a diazabicyclooctane compound and process of producing the same |
| JP7075884B2 (ja) * | 2015-08-10 | 2022-05-26 | サンド・アクチエンゲゼルシヤフト | アビバクタムナトリウムのｃ形 |
| CN106749242B (zh) * | 2015-11-23 | 2021-04-02 | 上海医药工业研究院 | 阿维巴坦中间体的制备方法 |
| CN105348173B (zh) * | 2015-12-02 | 2017-12-15 | 中山奕安泰医药科技有限公司 | 不对称催化氢化法合成阿维巴坦中间体5的方法 |
| US10472345B2 (en) | 2016-02-04 | 2019-11-12 | Merck Sharp & Dohme Corp. | Methods of preparing hydroxylamine derivatives useful in the preparation of anti-infective agents |
| GB201602145D0 (en) * | 2016-02-05 | 2016-03-23 | Achieve Pharma Uk Ltd | Salt |
| CN105753867B (zh) * | 2016-03-24 | 2018-03-27 | 齐鲁制药有限公司 | 一种改进的阿维巴坦钠中间体化合物的制备方法 |
| CN107325096B (zh) * | 2016-04-29 | 2020-11-03 | 正大天晴药业集团股份有限公司 | 一种阿维巴坦单钠盐的结晶 |
| EP3466950B1 (en) | 2016-06-03 | 2021-02-24 | Qilu Pharmaceutical Co., Ltd. | Novel beta-lactamase inhibitors |
| CN107540600B (zh) * | 2016-06-28 | 2019-07-09 | 新发药业有限公司 | 一种阿维巴坦中间体生产废液的回收利用方法 |
| CN107540601B (zh) * | 2016-06-28 | 2019-07-19 | 新发药业有限公司 | 5r-苄氧氨基哌啶-2s-甲酸酯及其草酸盐的便捷制备方法 |
| EP3504207B1 (en) * | 2016-08-26 | 2022-06-01 | Sandoz AG | Avibactam free acid |
| CN106432060A (zh) * | 2016-09-27 | 2017-02-22 | 海口南陆医药科技股份有限公司 | 一种阿维巴坦钠关键中间体的手性异构体的制备方法 |
| CN107880042A (zh) * | 2016-09-30 | 2018-04-06 | 上海复星星泰医药科技有限公司 | 阿维巴坦钠及其中间体化合物的制备方法 |
| CN106565712A (zh) * | 2016-09-30 | 2017-04-19 | 天津津泰生物医药技术有限公司 | 一种阿维巴坦钠中间体的制备方法 |
| CN108239089B (zh) * | 2016-12-27 | 2020-05-22 | 浙江医药股份有限公司新昌制药厂 | 一种阿维巴坦钠的合成方法 |
| CN108264480B (zh) * | 2016-12-30 | 2020-12-11 | 上海星泰医药科技有限公司 | 阿维巴坦钠中间体的制备方法 |
| CN106699756B (zh) * | 2016-12-30 | 2019-10-29 | 淄博鑫泉医药技术服务有限公司 | β内酰胺酶抑制剂阿维巴坦的合成方法 |
| US10434089B2 (en) | 2017-01-25 | 2019-10-08 | The Johns Hopkins University | Avibactam and carbapenems antibacterial agents |
| US10919893B2 (en) | 2017-02-08 | 2021-02-16 | Sandoz Ag | Process for the preparation of crystalline form C of avibactam sodium |
| CN106831772B (zh) * | 2017-03-04 | 2019-12-17 | 丽珠医药集团股份有限公司 | 一种阿维巴坦中间体的合成方法 |
| AU2018304907B2 (en) | 2017-07-21 | 2022-11-24 | Antabio Sas | Chemical compounds |
| CN109400521B (zh) * | 2017-08-18 | 2020-05-08 | 新发药业有限公司 | 一种改进的5r-苄氧氨基哌啶-2s-甲酸酯、其草酸盐的制备方法 |
| CN107417686B (zh) * | 2017-09-19 | 2020-04-28 | 北京化工大学 | 一种阿维巴坦钠的合成方法 |
| CN109678855B (zh) * | 2017-10-18 | 2020-07-17 | 新发药业有限公司 | 一种阿维巴坦中间体的制备方法 |
| CN109678856B (zh) * | 2017-10-18 | 2020-09-25 | 新发药业有限公司 | 一种阿维巴坦中间体的制备方法 |
| CN107941969B (zh) * | 2017-11-07 | 2021-03-02 | 中山奕安泰医药科技有限公司 | (2s,5r)-苯氧胺基哌啶-2-甲酰胺的检测方法 |
| CN107941944B (zh) * | 2017-11-23 | 2020-09-15 | 中山奕安泰医药科技有限公司 | 一种(2s,5r)-苄氧胺基哌啶-2-甲酸乙酯草酸盐的检测方法 |
| WO2019105479A1 (zh) | 2017-12-01 | 2019-06-06 | 南京明德新药研发股份有限公司 | 一种β-内酰胺酶抑制剂的晶型及其制备方法 |
| CN109912499B (zh) * | 2017-12-12 | 2021-04-27 | 江苏奥赛康药业有限公司 | 阿维巴坦中间体及其制备方法 |
| CN109928970B (zh) * | 2017-12-19 | 2020-04-28 | 新发药业有限公司 | 一种瑞利巴坦中间体的简便制备方法 |
| CN109956941B (zh) | 2017-12-25 | 2020-08-04 | 新发药业有限公司 | 一种阿维巴坦的简便制备方法 |
| CN109970625B (zh) * | 2017-12-28 | 2021-02-26 | 新发药业有限公司 | 一种5r-苄氧氨基哌啶-2s-甲酸或其衍生物的制备方法 |
| CN108373442B (zh) * | 2018-03-29 | 2020-07-03 | 台州职业技术学院 | 一种阿维巴坦中间异构体的回收方法 |
| CN108409736B (zh) * | 2018-05-16 | 2019-11-08 | 齐鲁天和惠世制药有限公司 | 一种喷雾干燥制备无定型阿维巴坦钠的方法 |
| EP3572411A1 (en) | 2018-05-21 | 2019-11-27 | Antabio SAS | Thiazole derivatives as metallo-beta-lactamase inhibitors |
| US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
| CA3113606A1 (en) * | 2018-09-21 | 2020-03-26 | Api Corporation | Method for producing amino acid derivatives |
| CN111072660B (zh) * | 2018-10-22 | 2021-05-18 | 新发药业有限公司 | 一种瑞来巴坦的简便制备方法 |
| CN109516987B (zh) * | 2018-12-26 | 2020-07-24 | 江西富祥药业股份有限公司 | 一种阿维巴坦中间体制备方法 |
| CN110437137A (zh) * | 2019-03-27 | 2019-11-12 | 成都克莱蒙医药科技有限公司 | 一种阿维巴坦中间体化合物的合成方法 |
| CN110577490B (zh) * | 2019-08-28 | 2020-09-22 | 山东安信制药有限公司 | 阿维巴坦中间体(2s,5s)-n-保护基-5-羟基-2-甲酸哌啶的合成方法 |
| CN110498762B (zh) * | 2019-08-28 | 2020-10-27 | 山东安信制药有限公司 | 一种(2s,5r)-5-[(苄氧基)氨基]-哌啶-2-甲酸乙酯的合成方法 |
| CN111116587A (zh) * | 2019-11-29 | 2020-05-08 | 北京耀诚惠仁科技有限公司 | 一种阿维巴坦中间体化合物的制备方法 |
| CN111777607A (zh) * | 2020-07-21 | 2020-10-16 | 海南海灵化学制药有限公司 | 一种阿维巴坦纳的制备方法 |
| CN115504913A (zh) * | 2021-06-23 | 2022-12-23 | 上海雨程生物科技有限公司 | 一种阿维巴坦钠中间体的合成方法 |
| CN115073458A (zh) * | 2022-07-04 | 2022-09-20 | 山东致泰医药技术有限公司 | 一种阿维巴坦钠的制备方法 |
| CN116003412A (zh) * | 2022-12-30 | 2023-04-25 | 常州红太阳药业有限公司 | 一种阿维巴坦钠及其中间体的合成方法 |
| CN117486881A (zh) * | 2023-12-28 | 2024-02-02 | 成都克莱蒙医药科技有限公司 | 一种阿维巴坦中间体的制备方法 |
| CN118307540B (zh) * | 2024-04-30 | 2024-10-15 | 浙江尖峰药业有限公司 | 一种阿维巴坦钠的合成方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| AU707748B2 (en) | 1994-03-25 | 1999-07-22 | Isotechnika Inc. | Enhancement of the efficacy of drugs by deuteration |
| TW473479B (en) | 1997-12-19 | 2002-01-21 | Takeda Chemical Industries Ltd | Phosphonocephem derivatives, their production and use |
| FR2812635B1 (fr) * | 2000-08-01 | 2002-10-11 | Aventis Pharma Sa | Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens |
| AU2001277753A1 (en) | 2000-08-10 | 2002-02-25 | Takeda Chemical Industries Ltd. | Phosphonocephem compound |
| FR2835186B1 (fr) | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases |
| AU2004282189B2 (en) * | 2003-10-17 | 2011-11-17 | Incyte Holdings Corporation | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases |
| WO2006032466A2 (en) * | 2004-09-24 | 2006-03-30 | Actelion Pharmaceuticals Ltd | New bicyclic antibiotics |
| CN101258157A (zh) * | 2005-05-24 | 2008-09-03 | 阿斯利康(瑞典)有限公司 | 具有抗菌活性的氨基哌啶喹啉及其氮杂等构类似物 |
| WO2008042227A1 (en) | 2006-09-28 | 2008-04-10 | Med Institute, Inc. | Medical device including an anesthetic and method of preparation thereof |
| FR2921060B1 (fr) | 2007-09-14 | 2012-06-15 | Novexel | Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires |
| CN101918407B (zh) * | 2008-01-18 | 2014-02-26 | 默沙东公司 | β-内酰胺酶抑制剂 |
| WO2010126820A2 (en) * | 2009-04-30 | 2010-11-04 | Merck Sharp & Dohme Corp. | Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids |
| CN102781451A (zh) | 2009-09-21 | 2012-11-14 | 阿斯利康(瑞典)有限公司 | 使用头孢洛林用于治疗细菌感染的组合物和方法 |
| FR2951171A1 (fr) * | 2009-10-09 | 2011-04-15 | Novexel | Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation |
| EP2584903B1 (en) * | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
| RU2591701C2 (ru) * | 2010-12-22 | 2016-07-20 | Мейдзи Сейка Фарма Ко., Лтд. | Оптически активное производное диазабициклооктана и способ его получения |
| WO2012133486A1 (ja) * | 2011-03-31 | 2012-10-04 | 株式会社カネカ | 環状アミン化合物の製造法 |
| ES2560404T3 (es) * | 2011-06-17 | 2016-02-18 | Astrazeneca Ab | Procesos para preparar compuestos heterocíclicos, incluida trans-7-oxo-6-(sulfooxi)-1,6-diazabiciclo[3,2,1]octano-2-carboxamida y sales de la misma |
| JP6005157B2 (ja) * | 2011-08-25 | 2016-10-12 | テレフオンアクチーボラゲット エルエム エリクソン（パブル） | 深度マップ符号化および復号化 |
| CA2845108C (en) * | 2011-08-30 | 2015-06-16 | Wockhardt Limited | 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections |
-
2012
- 2012-06-15 ES ES12727922.2T patent/ES2560404T3/es active Active
- 2012-06-15 AU AU2012270051A patent/AU2012270051B2/en active Active
- 2012-06-15 RU RU2017102358A patent/RU2769076C2/ru active
- 2012-06-15 KR KR1020137033079A patent/KR102143660B1/ko active IP Right Grant
- 2012-06-15 WO PCT/GB2012/051388 patent/WO2012172368A1/en active Application Filing
- 2012-06-15 RU RU2014101244A patent/RU2610091C2/ru active
- 2012-06-15 SG SG2013089578A patent/SG195289A1/en unknown
- 2012-06-15 JP JP2014515292A patent/JP6023800B2/ja active Active
- 2012-06-15 EP EP12727922.2A patent/EP2721005B1/en active Active
- 2012-06-15 BR BR112013032415-5A patent/BR112013032415B1/pt active IP Right Grant
- 2012-06-15 CA CA2780403A patent/CA2780403C/en active Active
- 2012-06-15 MY MYPI2013702441A patent/MY165730A/en unknown
- 2012-06-15 TW TW101121652A patent/TWI565706B/zh active
- 2012-06-15 CN CN201510720279.5A patent/CN105294690B/zh active Active
- 2012-06-15 US US13/524,007 patent/US8829191B2/en active Active
- 2012-06-15 CN CN201280029765.7A patent/CN103649051B/zh active Active
- 2012-06-15 MX MX2013014114A patent/MX361020B/es active IP Right Grant
- 2012-06-18 AR ARP120102159 patent/AR086972A1/es active IP Right Grant
-
2013
- 2013-12-05 IL IL229815A patent/IL229815A/en active IP Right Grant
-
2014
- 2014-02-14 US US14/180,656 patent/US8969566B2/en active Active
- 2014-10-10 HK HK14110118.0A patent/HK1196615A1/zh unknown
-
2015
- 2015-01-05 US US14/589,194 patent/US9284314B2/en active Active
-
2016
- 2016-02-10 US US15/040,654 patent/US9695122B2/en active Active
- 2016-10-07 JP JP2016199214A patent/JP6342462B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR086972A1 (es) | Procesos para preparar compuestos heterociclicos, que incluyen trans-7-oxo-6-(sulfooxi)-1,6-diazabiciclo[3,2,1]octano-2-carboxamida y sales de la misma | |
| AR058769A1 (es) | Inhibidores de peptidil-deformilasa(pdf),utiles para el tratamiento de la tuberculosis y composiciones farmaceuticas que los contienen. | |
| CO6251254A2 (es) | Uso de inhibidores de piridopirimidinona de pi3k en el tratamiento del cancer | |
| CA2572208A1 (en) | 3-carbamoyl-2-pyridone derivative | |
| AR086367A1 (es) | Compuestos de pirrolidinil urea y pirrolidinil tiourea como inhibidores de cinasa trka | |
| RU2018145761A (ru) | Сульфонамидное соединение или его соль | |
| NZ717119A (en) | Aryl-or heteroaryl-substituted benzene compounds | |
| AR058379A1 (es) | Derivados de arilpropionamida arilacrilamida arilpropinamida o arilmetilurea como inhibidores del factor xia. proceso de obtencion y composiciones farmaceuticas. | |
| AR079752A1 (es) | Prodrogas de sales de amonio cuaternario | |
| RU2015121431A (ru) | Замещенные производные индол-5-ола и их терапевтическое применение | |
| CA2517517A1 (en) | P38 inhibitors and methods of use thereof | |
| AR038881A1 (es) | Compuestos que modulan la actividad de ppar, composicion farmaceutica que los contiene y un procedimiento para la preparcion de aquellos | |
| AR070502A1 (es) | Derivado de sulfonilmalonamida, su uso farmaceutico y composiciones que los comprenden | |
| AR061873A1 (es) | Derivados de pirrolotriazina inhibidores de tirosinquinasas, composiciones farmaceuticas que los contienen utiles para el tratamiento de enfermedades proliferativas. | |
| AR043674A1 (es) | Derivados de piridazinona como inhibidores no nucleosidos de la transcriptasa reversa | |
| RU2015106605A (ru) | Соединения замещенных пиразолонов и способы использования | |
| AR083842A1 (es) | Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a las angiogenesis | |
| JP2014524934A5 (es) | ||
| CA2943022C (en) | Benzo[g]pyrido[2,1-b] quinazoline carboxamide compounds which inhibit rna polymerase, compositions including such compounds, and their use | |
| AR053364A1 (es) | Compuesto de 1h-imidazo 84,5-c) piridin -2- ilo, composicion farmaceutica que lo comprende, proceso para prepararla y su uso para preparar un medicamento para tratamiento de cancer o artritis | |
| RU2010150345A (ru) | Производные хиназолина | |
| ECSP099767A (es) | Derivados de n' - (fenil) -n- (morfolin-4-il-piridin-2-il) -pirimidina-2, 4-diamina como inhibidores de quinasas ephb4 para el tratamiento de afecciones proliferativas | |
| AR080151A1 (es) | Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia | |
| DOP2012000053A (es) | Derivados de (tio) morfolina como moduladores de s1p | |
| RU2008102156A (ru) | НОВЫЕ ФУРО- И ТИЕНО[2,3-b]-ХИНОЛИН-2-КАРБОКСАМИДЫ, СПОСОБ ПОЛУЧЕНИЯ И ПРОТИВОТУБЕРКУЛЕЗНАЯ АКТИВНОСТЬ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |